Skip to main content
TipRanks
Go Ultimate75% OFF

Establishment Labs Holdings (3E0) AI Stock Analysis

1 Followers
DE:3E0

Establishment Labs Holdings

(Frankfurt:3E0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
U.S. and international revenue growthStrong growth across both the U.S. and international businesses indicates expanding market reach rather than dependence on one geography. Continued account gains and international expansion can support durable revenue growth as Motiva adoption and procedure volumes increase over the next several quarters.
Negative Factors
Persistent GAAP lossesThe company has not yet converted strong gross margins and improving revenue into sustainable GAAP earnings. Continued losses constrain internally generated capital, increase reliance on external financing, and leave execution vulnerable if operating expenses do not scale efficiently with growth.

Establishment Labs Holdings (3E0) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%DE:3E0+63.24%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 2.11B
Dividend Yield
―
Average Volume (3M)
127
Price to Earnings (P/E)
-55.3
Beta (1Y)
0.67
Revenue Growth
31.94%
EPS Growth
57.98%
Country
Germany
Employees
1,004
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Establishment Labs Holdings Business Overview & Revenue Model

Company Description

Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-fill...

Establishment Labs Holdings Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:2.71%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial year-over-year revenue growth, major U.S. and minimally invasive momentum, improved adjusted profitability, first-ever positive free cash flow, raised 2026 guidance and a 25% growth outlook for 2027. The main challenges were seasonal sequential softness, Middle East weakness, lower-than-previously-guided gross margin, ongoing GAAP losses and uncertainty around the timing of reconstruction approval and hospital adoption.

Positive Updates

Strong Third-Quarter Revenue Growth
Q3 revenue was $72 million, an increase of 33.9% year-over-year from $53.8 million, driven by U.S. market share gains and growth across the outside-the-U.S. business.

Negative Updates

Seasonal Sequential Revenue Decline
Sequentially, minimally invasive revenue was lower in Q3 because of normal summer seasonality in OUS direct markets. Management said Q3 is typically the softest quarter of the year and that the seasonal weakness affected overall procedure levels in Europe.

Company Guidance

Management raised full year 2026 revenue guidance to more than $274 million from $269 million to $271 million, expects minimally invasive revenue to exceed $40 million versus previous guidance of more than $35 million, and expects full year adjusted gross margin of approximately 70.7%, adjusted operating expenses of $195 million to $200 million, positive adjusted EBITDA for the full year and positive free cash flow in fiscal 2027. Management expects growth in 2027 to be 25%, with 50 to 100 basis points of gross margin improvement, expects 500 surgeons trained on Preserve by year-end, and remains confident in mid-single-digit growth for the year in distributor markets; additional Motiva sizes are expected to be commercially available before year-end, with reconstruction approval expected either the end of this year or the beginning of next.

Establishment Labs Holdings Risk Analysis

Establishment Labs Holdings disclosed 66 risk factors in its most recent earnings report. Establishment Labs Holdings reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Establishment Labs Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:3E0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CNMDCNMD69Neutral$1.51B20.907.07%―1.93%16.93%
INMDINMD69Neutral$763.61M10.7911.36%―2.50%-43.86%
AXGNAXGN68Neutral$3.34B-86.05-11.34%―24.32%-1274.47%
BFLYBFLY67Neutral$1.63B-29.04-28.22%―39.35%38.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IARTIART44Neutral$1.12B85.821.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%DE:3E0CNMDIARTAXGNINMDBFLYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:3E0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:3E0Establishment Labs Holdings61.3823.7863.24%
CNMDConmed Corporation50.598.9621.52%
IARTIntegra Lifesciences14.402.6722.76%
AXGNAxoGen55.9332.36137.29%
INMDInmode13.27-0.64-4.60%
BFLYButterfly Network, Inc.6.084.11208.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.